OKT3 treatment in refractory pediatric heart transplant rejection.

[1]  W. Mahle,et al.  Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[2]  J. Saffitz,et al.  Non-ischemic left ventricular dysfunction after pediatric cardiac transplantation: treatment with plasmapheresis and OKT3. , 2004, The Journal of Heart and Lung Transplantation.

[3]  S. Gundry,et al.  Total lymphoid irradiation for refractory rejection in pediatric heart transplantation. , 2002, The Annals of thoracic surgery.

[4]  J. Tomaszewski,et al.  Successful reversal of severe refractory cardiac allograft rejection by photopheresis. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[5]  R. Novick,et al.  The Registry of the International Society for Heart and Lung Transplantation: eighteenth Official Report-2001. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  R. Hetzer,et al.  Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  D. Ivy,et al.  Transplant coronary artery disease in pediatrics: favorable outcome with medical therapy. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  L. Bailey,et al.  Late rejection is a predictor of transplant coronary artery disease in children. , 2001, Journal of the American College of Cardiology.

[9]  P. McCarthy,et al.  Efficacy of tacrolimus in patients with steroid-resistant cardiac allograft cellular rejection. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  C. Mavroudis,et al.  Reversal of severe late left ventricular failure after pediatric heart transplantation and possible role of plasmapheresis. , 2000, The American journal of cardiology.

[11]  R. Loertscher,et al.  Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy. , 1997, Clinical transplantation.

[12]  D. Renlund,et al.  Methotrexate therapy in pediatric heart transplantation as treatment of recurrent mild to moderate acute cellular rejection. , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[13]  B. Meiser,et al.  How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation? , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[14]  Y. Liao,et al.  Risk/benefit ratio of perioperative OKT3 in cardiac transplantation. , 1993, Transplantation proceedings.

[15]  R. Fisher,et al.  Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. , 1990, The New England journal of medicine.

[16]  M. Hammond,et al.  A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. , 1990, The Journal of heart transplantation.

[17]  A. Menter,et al.  Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis. A word of caution in light of the expanding use of this 'steroid-sparing' agent. , 1990, Archives of internal medicine.

[18]  B. Radovancević,et al.  Clinical experience with Muromonab-CD3 monoclonal antibody (OKT3) in heart transplantation. , 1989, The Journal of heart transplantation.

[19]  B. McManus,et al.  Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience. , 1989, The Journal of heart transplantation.

[20]  J. Sinnott,et al.  The treatment of advanced cardiac allograft rejection. , 1988, The Annals of thoracic surgery.

[21]  L. Gray,et al.  USE OF OKT3 MONOCLONAL ANTIBODY IN THE TREATMENT OF ACUTE CARDIAC ALLOGRAFT REJECTION , 1988, Transplantation.